Heng Xu

905 citations

56 papers · 728 indexed · h-index 18

Co-authors: Songwen Lin Yi Dong Jiajing Chen Xiaoguang Chen Ming Ji Kehui Zhang Deyu Wu Meidong Lang
Topics: PI3K/AKT/mTOR signaling in cancer (16 papers)Catalytic C–H Functionalization Methods (13 papers)Synthesis and Catalytic Reactions (10 papers)
Cited by: Organic Chemistry Toxicology Molecular Biology
Journals: Chemical Communications Journal of Medicinal Chemistry The Journal of Organic Chemistry
Partner nations: China United Kingdom India

In The Last Decade

Heng Xu

49 papers receiving 720 citations

Peers

Countries citing papers authored by Heng Xu

Since Specialization

Citations

This map shows the geographic impact of Heng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Xu more than expected).

Fields of papers citing papers by Heng Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Xu. The network helps show where Heng Xu may publish in the future.

Co-authorship network of co-authors of Heng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Heng Xu. A scholar is included among the top collaborators of Heng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Xu. Heng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of Novel PI3K/BRD4 Dual Inhibitors for Esophageal Cancer: Rational Design, Optimization, and Senescence-Inducing Mechanisms 2025 ·Journal of Medicinal Chemistry ·(unknown),Yihui Yang,Li Wan,Songwen Lin,(unknown),(unknown),Jing Ge,Sheng Li,Jinhua Wang,Heng Xu	0
2	Integrated molecular and microenvironmental drivers of drug resistance in gastrointestinal cancers: mechanisms, immunotherapy challenges, and precision strategies 2025 ·Frontiers in Oncology ·Heng Xu,(unknown),(unknown),Kangling Zhang,(unknown),(unknown),(unknown),Zhenkun Zhuang,Xiaolin Zhong	0
3	Design, synthesis and evaluation of a fluorescent PI3K inhibitor as a dual-function agent toward Cancer Theranostics 2025 ·Bioorganic & Medicinal Chemistry Letters ·Ge Shi,Hua Tian,(unknown),Dan Liu,Zhen Yan,Min Yang,Heng Xu	0
4	Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia 2025 ·Journal of Medicinal Chemistry ·Hua Tian,Yichen Liu,Songwen Lin,(unknown),Qinghua Zhang,(unknown),(unknown),(unknown),Kehui Zhang,Ge Shi,Lijun Luo,(unknown),Sheng Li,Ming Ji,Heng Xu	2
5	Rhodium-catalyzed site-selective cross-couplings of indoles and pyridotriazoles through carbene insertion 2024 ·Chinese Chemical Letters ·Huafeng Tian,(unknown),Ge Shi,Heng Xu,Yi Dong	0
6	Design, synthesis and biological evaluation of a novel PSMA–PI3K small molecule drug conjugate 2024 ·RSC Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Songwen Lin,Deyu Wu,Ming Ji,Heng Xu	2
7	S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer 2023 ·Pharmaceuticals ·Zhenyan Hou,Songwen Lin,Tingting Du,Mingjin Wang,Weida Wang,(unknown),Nina Xue,Yichen Liu,(unknown),Heng Xu,Xiaoguang Chen	2
8	Design, synthesis, and biological evaluation of novel bivalent PI3K inhibitors for the potential treatment of cancer 2023 ·Bioorganic Chemistry ·Liang Xia,Lin Jiang,Tingting Du,Songwen Lin,(unknown),(unknown),Hua Tian,Kehui Zhang,Deyu Wu,Sheng Li,Ming Ji,Xiaoguang Chen,Heng Xu	6
9	Rational design and optimization of novel 4-methyl quinazoline derivatives as PI3K/HDAC dual inhibitors with benzamide as zinc binding moiety for the treatment of acute myeloid leukemia 2023 ·European Journal of Medicinal Chemistry ·Kehui Zhang,Rui Huang,Ming Ji,Songwen Lin,Fangfang Lai,Deyu Wu,Hua Tian,(unknown),(unknown),Jiaqi Hu,Sheng Li,Yan Li,Xiaoguang Chen,Heng Xu	7
10	A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models 2021 ·Acta Pharmaceutica Sinica B ·Ming Ji,Dongjie Wang,Songwen Lin,Chunyang Wang,Ling Li,Zhihui Zhang,Jing Jin,Deyu Wu,Yi Dong,Heng Xu,Duo Lü,Xiaoguang Chen	16
11	A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity 2020 ·Cancer Letters ·Tingting Du,Songwen Lin,Ming Ji,Nina Xue,Yichen Liu,Zhihui Zhang,Kehui Zhang,Jingbo Zhang,Yan Zhang,Qinghua Wang,Sheng Li,Yan Li,Duo Lü,Xiaoguang Chen,Heng Xu	18
12	Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors 2020 ·Bioorganic & Medicinal Chemistry ·Yan Sun,Rong Fu,Songwen Lin,Jingbo Zhang,Ming Ji,Yan Zhang,Deyu Wu,Kehui Zhang,Hua Tian,Mingyi Zhang,Sheng Li,Yan Li,Jing Jin,Xiaoguang Chen,Heng Xu	19
13	CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis 2019 ·Neurobiology of Disease ·Lu Wang,Hanyu Yang,Caixia Zang,Yi Dong,(unknown),Jiajing Chen,Yue Wang,Hui Liu,Zihong Zhang,Heng Xu,Xiu‐Qi Bao,Dan Zhang	14
14	Enhanced bioreduction-responsive biodegradable diselenide-containing poly(ester urethane) nanocarriers 2017 ·Biomaterials Science ·Chao Wei,Yan Zhang,Zhongchen Song,Yiru Xia,Heng Xu,Meidong Lang	30
15	Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors 2017 ·Bioorganic & Medicinal Chemistry ·Songwen Lin,Chunyang Wang,Ming Ji,Deyu Wu,(unknown),Sheng Li,(unknown),Yi Dong,Kehui Zhang,Yakun Yang,Yan Li,Xiaoguang Chen,Heng Xu	6
16	Preparation, degradation and in vitro release of ciprofloxacin-eluting ureteral stents for potential antibacterial application 2016 ·Materials Science and Engineering C ·Xiaofei Ma,Yan Xiao,Heng Xu,Kun Lei,Meidong Lang	36
17	Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·Songwen Lin,(unknown),Peng Liu,Jing Tao,(unknown),Xiujie Liu,(unknown),Heng Xu	7
18	Synthesis and structure–activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives 2014 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Songwen Lin,Peng Liu,Jing Tao,(unknown),Heng Xu	14
19	Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Baowei Zhao,(unknown),Xuesong Xu,Guanghui Deng,Chengyong Li,(unknown),Feng Ren,Hailong Wang,Heng Xu,Yan Xu,Haibo Zhang,Jia‐Ning Xiang,John D. Elliott,Taylor B. Guo,Yonggang Zhao,Wei Zhang,Hongtao Lu,Xichen Lin	14
20	Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein 2010 ·Molecular and Cellular Biochemistry ·Guohui Li,(unknown),Xiaowei Liu,Bingfang Zhang,Dandan Yin,Fei He,(unknown),(unknown),Heng Xu,Qiang Liu,(unknown),Xiaoli Niu,Li Zhang,Li Liu,(unknown),Hua Han,Yingmin Liang	21

About Heng Xu

Heng Xu is a scholar working on Organic Chemistry, Genetics and Molecular Biology, having authored 56 papers that have together received 728 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (16 papers), Catalytic C–H Functionalization Methods (13 papers) and Synthesis and Catalytic Reactions (10 papers). The work is most often cited by research in Organic Chemistry (371 citations), Toxicology (19 citations) and Molecular Biology (328 citations). Heng Xu has collaborated with scholars based in China, United Kingdom and India. Frequent co-authors include Songwen Lin, Yi Dong, Jiajing Chen, Xiaoguang Chen, Ming Ji, Kehui Zhang, Deyu Wu, Meidong Lang, Jingbo Zhang and Jing Jin. Their work appears in journals such as Chemical Communications, Journal of Medicinal Chemistry and The Journal of Organic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact